Want to see HK:1548 full AI Analyst Report?
Genscript Biotech (1548) Ratios
Genscript Biotech Ratios
HK:1548's free cash flow for Q2 2026 was $9.10M. For the 2026 fiscal year, HK:1548's free cash flow was decreased by $-47.58M and operating cash flow was $56.68M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 1.47 | 2.72 | 4.76 | 3.23 | 3.97 |
| Quick Ratio | 1.41 | 2.62 | 4.65 | 3.12 | 3.86 |
| Cash Ratio | 0.24 | 0.43 | 2.92 | 1.88 | 2.86 |
| Solvency Ratio | -0.52 | 3.17 | -0.02 | -0.15 | -0.38 |
| Operating Cash Flow Ratio | 0.45 | 0.25 | -0.58 | -0.22 | -0.33 |
| Short-Term Operating Cash Flow Coverage | 0.70 | 0.85 | -5.03 | -3.57 | -262.55 |
| Net Current Asset Value | $ 180.58M | $ -119.93M | $ 1.01B | $ 581.24M | $ 792.88M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.05 | 0.14 | 0.12 | 0.14 | 0.07 |
| Debt-to-Equity Ratio | 0.07 | 0.17 | 0.30 | 0.35 | 0.15 |
| Debt-to-Capital Ratio | 0.06 | 0.14 | 0.23 | 0.26 | 0.13 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.12 | 0.17 | 0.21 | 0.10 |
| Financial Leverage Ratio | 1.23 | 1.22 | 2.44 | 2.52 | 2.14 |
| Debt Service Coverage Ratio | 0.55 | 0.70 | -3.00 | -8.21 | -164.96 |
| Interest Coverage Ratio | 14.74 | 1.16 | 0.95 | -33.02 | -159.50 |
| Debt to Market Cap | 0.16 | 0.24 | 0.07 | 0.04 | 0.01 |
| Interest Debt Per Share | 0.13 | 0.34 | 0.21 | 0.17 | 0.08 |
| Net Debt to EBITDA | 0.26 | 8.40 | 4.13 | 1.73 | 2.15 |
| Profitability Margins | |||||
| Gross Profit Margin | 57.65% | 45.77% | 32.24% | 48.60% | 57.65% |
| EBIT Margin | 26.60% | 1.56% | -38.53% | -70.00% | -105.08% |
| EBITDA Margin | 34.32% | 11.85% | -29.71% | -62.18% | -97.38% |
| Operating Profit Margin | 26.60% | 1.56% | 3.12% | -70.02% | -77.39% |
| Pretax Profit Margin | -49.04% | -28.73% | -41.81% | -68.99% | -105.56% |
| Net Profit Margin | -55.53% | 498.22% | -11.37% | -36.26% | -73.19% |
| Continuous Operations Profit Margin | -55.49% | -29.23% | 19.40% | -68.40% | -105.76% |
| Net Income Per EBT | 113.24% | -1734.15% | 27.20% | 52.55% | 69.33% |
| EBT Per EBIT | -184.34% | -1840.09% | -1339.92% | 98.53% | 136.40% |
| Return on Assets (ROA) | -10.98% | 56.11% | -2.82% | -8.91% | -16.06% |
| Return on Equity (ROE) | -13.46% | 68.54% | -6.86% | -22.45% | -34.29% |
| Return on Capital Employed (ROCE) | 6.18% | 0.19% | 0.91% | -21.90% | -20.83% |
| Return on Invested Capital (ROIC) | 5.54% | 0.18% | 0.89% | -22.50% | -21.31% |
| Return on Tangible Assets | -11.01% | 56.27% | -2.84% | -9.00% | -16.35% |
| Earnings Yield | -15.41% | 107.38% | -1.86% | -3.40% | -3.99% |
| Efficiency Ratios | |||||
| Receivables Turnover | 7.17 | 5.01 | 3.84 | 6.00 | 3.44 |
| Payables Turnover | 11.05 | 10.80 | 7.25 | 5.77 | 6.88 |
| Inventory Turnover | 10.26 | 10.37 | 5.43 | 5.37 | 4.68 |
| Fixed Asset Turnover | 1.54 | 1.00 | 1.12 | 1.00 | 1.01 |
| Asset Turnover | 0.20 | 0.11 | 0.25 | 0.25 | 0.22 |
| Working Capital Turnover Ratio | 2.22 | 0.50 | 0.55 | 0.51 | 0.52 |
| Cash Conversion Cycle | 53.46 | 74.31 | 112.00 | 65.57 | 131.02 |
| Days of Sales Outstanding | 50.94 | 72.89 | 95.14 | 60.83 | 106.08 |
| Days of Inventory Outstanding | 35.56 | 35.21 | 67.18 | 68.02 | 78.00 |
| Days of Payables Outstanding | 33.04 | 33.78 | 50.32 | 63.28 | 53.06 |
| Operating Cycle | 86.50 | 108.10 | 162.32 | 128.85 | 184.08 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 0.15 | 0.03 | -0.14 | -0.06 | -0.07 |
| Free Cash Flow Per Share | 0.11 | -0.03 | -0.21 | -0.16 | -0.13 |
| Dividend Paid and CapEx Coverage Ratio | 3.88 | 0.51 | -1.82 | -0.56 | -1.03 |
| Capital Expenditure Coverage Ratio | 3.88 | 0.51 | -1.82 | -0.56 | -1.03 |
| Operating Cash Flow Coverage Ratio | 1.26 | 0.10 | -0.69 | -0.34 | -0.87 |
| Operating Cash Flow to Sales Ratio | 0.34 | 0.13 | -0.34 | -0.19 | -0.28 |
| Free Cash Flow Yield | 6.99% | -2.62% | -8.66% | -5.04% | -3.00% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.38 | 0.93 | -53.79 | -29.40 | -25.04 |
| Price-to-Sales (P/S) Ratio | 3.60 | 4.64 | 6.12 | 10.66 | 18.32 |
| Price-to-Book (P/B) Ratio | 0.87 | 0.64 | 3.69 | 6.60 | 8.59 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 14.31 | -38.16 | -11.55 | -19.83 | -33.28 |
| Price-to-Operating Cash Flow Ratio | 10.62 | 36.46 | -17.90 | -55.44 | -65.65 |
| Price-to-Earnings Growth (PEG) Ratio | -0.01 | -0.03 | 0.91 | 0.76 | -0.39 |
| Enterprise Value Multiple | 10.76 | 47.57 | -16.46 | -15.41 | -16.67 |
| Enterprise Value | 3.54B | 3.35B | 4.11B | 6.00B | 7.96B |
| EV to EBITDA | 10.76 | 47.57 | -16.46 | -15.41 | -16.67 |
| EV to Sales | 3.69 | 5.64 | 4.89 | 9.58 | 16.23 |
| EV to Free Cash Flow | 14.66 | -46.35 | -9.23 | -17.82 | -29.49 |
| EV to Operating Cash Flow | 10.88 | 44.28 | -14.31 | -49.84 | -58.17 |
| Tangible Book Value Per Share | 1.83 | 1.98 | 0.96 | 0.64 | 0.66 |
| Shareholders’ Equity Per Share | 1.83 | 1.98 | 0.66 | 0.48 | 0.52 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.13 | -0.02 | -0.01 | 0.01 | -0.00 |
| Revenue Per Share | 0.44 | 0.27 | 0.40 | 0.30 | 0.24 |
| Net Income Per Share | -0.25 | 1.36 | -0.05 | -0.11 | -0.18 |
| Tax Burden | 1.13 | -17.34 | 0.27 | 0.53 | 0.69 |
| Interest Burden | -1.84 | -18.40 | 1.09 | 0.99 | 1.00 |
| Research & Development to Revenue | 0.07 | 0.09 | 0.52 | 0.62 | 0.73 |
| SG&A to Revenue | 0.24 | 0.34 | 0.25 | 0.29 | 0.27 |
| Stock-Based Compensation to Revenue | 0.02 | 0.03 | 0.07 | 0.10 | 0.08 |
| Income Quality | -0.69 | 0.03 | 0.82 | 0.53 | 0.38 |
Currency in USD
